Genetic Technologies Operating Income 2010-2021 | GENE
Genetic Technologies operating income from 2010 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Genetic Technologies Annual Operating Income
(Millions of US $) |
| 2021 |
$-5 |
| 2020 |
$-5 |
| 2019 |
$-5 |
| 2018 |
$-5 |
| 2017 |
$-6 |
| 2016 |
$-7 |
| 2015 |
$-8 |
| 2014 |
$-10 |
| 2013 |
$-14 |
| 2012 |
$-14 |
| 2011 |
$-13 |
| 2010 |
$-10 |
| 2009 |
$-9 |
Genetic Technologies Quarterly Operating Income
(Millions of US $) |
| 2021-12-31 |
|
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| 2010-06-30 |
|
| 2009-12-31 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.020B |
$0.000B |
|
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
|
